Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 ...

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients ...

First clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutations Global pivotal Phase 3 monotherapy study for ...

Syndax Pharmaceuticals Inc. (SNDX) ...

Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...

New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

The global microbiology culture market propelled by increasing demand across sectors such as pharmaceuticals, food and ...

Cambridge-based Draper Labs is set to launch their NASA-funded CP-12 mission in 2026, racing Texas-based Firefly Aerospace to ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...